145 related articles for article (PubMed ID: 11783501)
1. The role of deoxycytidine kinase in gemcitabine cytotoxicity.
van der Wilt CL; Kroep JR; Bergman AM; Loves WJ; Alvarez E; Talianidis I; Eriksson S; van Groeningen CJ; Pinedo HM; Peters GJ
Adv Exp Med Biol; 2000; 486():287-90. PubMed ID: 11783501
[No Abstract] [Full Text] [Related]
2. Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase.
Sigmond J; Bergman AM; Leon LG; Loves WJ; Hoebe EK; Peters GJ
Anticancer Drugs; 2010 Jul; 21(6):591-9. PubMed ID: 20436341
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology and pharmacogenetics of gemcitabine.
Wong A; Soo RA; Yong WP; Innocenti F
Drug Metab Rev; 2009; 41(2):77-88. PubMed ID: 19514966
[TBL] [Abstract][Full Text] [Related]
4. Induction of in vivo resistance against gemcitabine (dFdC, 2',2'-difluoro-deoxycytidine).
Ruiz van Haperen VW; Veerman G; van Moorsel CJ; Peters GJ
Adv Exp Med Biol; 1998; 431():637-40. PubMed ID: 9598143
[No Abstract] [Full Text] [Related]
5. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines.
Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Peters GJ
Adv Exp Med Biol; 1994; 370():139-43. PubMed ID: 7660877
[No Abstract] [Full Text] [Related]
7. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine: new indication. Relapsed ovarian cancer: simply more toxic. Increases haematologic toxicity but not overall survival.
Prescrire Int; 2009 Aug; 18(102):156. PubMed ID: 19746525
[No Abstract] [Full Text] [Related]
9. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine-induced severe extremity edema with muscle contractures and subsequent prevention with prednisone.
Geffen DB; Horowitz J
Isr Med Assoc J; 2000 Jul; 2(7):552-3. PubMed ID: 10979335
[No Abstract] [Full Text] [Related]
11. Regulation of deoxycytidine kinase by deoxycytidine and deoxycytidine 5' triphosphate in whole leukemia and tumor cells.
Heinemann V; Schulz L; Issels RD; Wilmanns W
Adv Exp Med Biol; 1998; 431():249-53. PubMed ID: 9598069
[No Abstract] [Full Text] [Related]
12. Combination chemotherapy studies with gemcitabine.
van Moorsel CJ; Veerman G; Bergman AM; Guechev A; Vermorken JB; Postmus PE; Peters GJ
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-17-S7-23. PubMed ID: 9194475
[TBL] [Abstract][Full Text] [Related]
13. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model.
Kanzawa F; Saijo N
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-8-S7-16. PubMed ID: 9194474
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
Kroep JR; Loves WJ; van der Wilt CL; Alvarez E; Talianidis I; Boven E; Braakhuis BJ; van Groeningen CJ; Pinedo HM; Peters GJ
Mol Cancer Ther; 2002 Apr; 1(6):371-6. PubMed ID: 12477049
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of gemcitabine in lung cancer.
Bunn PA
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-1. PubMed ID: 9207307
[No Abstract] [Full Text] [Related]
16. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
Al-Madhoun AS; van der Wilt CL; Loves WJ; Padron JM; Eriksson S; Talianidis I; Peters GJ
Biochem Pharmacol; 2004 Aug; 68(4):601-9. PubMed ID: 15276067
[TBL] [Abstract][Full Text] [Related]
17. Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors.
Minami K; Shinsato Y; Yamamoto M; Takahashi H; Zhang S; Nishizawa Y; Tabata S; Ikeda R; Kawahara K; Tsujikawa K; Chijiiwa K; Yamada K; Akiyama S; Pérez-Torras S; Pastor-Anglada M; Furukawa T; Yasuo T
J Pharmacol Sci; 2015 Mar; 127(3):319-25. PubMed ID: 25837929
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine--status of preclinical studies and perspectives for future clinical applications of this novel nucleoside analog. Symposium proceedings. Amsterdam, The Netherlands, March 15, 1994.
Semin Oncol; 1995 Aug; 22(4 Suppl 11):1-82. PubMed ID: 7481838
[No Abstract] [Full Text] [Related]
19. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
Vena F; Bayle S; Nieto A; Quereda V; Aceti M; Frydman SM; Sansil SS; Grant W; Monastyrskyi A; McDonald P; Roush WR; Teng M; Duckett D
Mol Cancer Ther; 2020 Aug; 19(8):1623-1635. PubMed ID: 32430484
[TBL] [Abstract][Full Text] [Related]
20. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
Costantino CL; Witkiewicz AK; Kuwano Y; Cozzitorto JA; Kennedy EP; Dasgupta A; Keen JC; Yeo CJ; Gorospe M; Brody JR
Cancer Res; 2009 Jun; 69(11):4567-72. PubMed ID: 19487279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
